問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

Division of General Internal Medicine

更新時間：2025-12-16

李妮鍾LEE, NI-CHUNG
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years

Recruiting Trial

14Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李妮鍾

List

31Cases

2021-07-01 - 2024-05-13

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2008-01-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2016-06-01 - 2018-12-31

IIT

Phase II

A clinical trial for treatment of aromatic L-amino acid decarboxylase (AADC) deficiency using AAV2-hAADC - An expansion

  • Condition/Disease

    Aromatic L-amino acid decarboxylase (AADC) deficiency

  • Test Drug

    AADV2-hAADC

Participate Sites
1Sites

Terminated1Sites

2014-07-10 - 2021-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-02-26 - 2021-11-25

Phase III

A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo

  • Condition/Disease

    Late Onset Pompe Disease

  • Test Drug

    AT2221/ATB200

Participate Sites
1Sites

Recruiting1Sites

2018-09-01 - 2018-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-02-01 - 2024-01-31

Phase I/II

A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects With Phenylketonuria

  • Condition/Disease

    Phenylketonuria (PKU)

  • Test Drug

    BMN 307

Participate Sites
2Sites

Not yet recruiting2Sites

2018-09-01 - 2021-06-15

Phase III

A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2

  • Condition/Disease

    Spinal Muscular Atrophy

  • Test Drug

    AVXS-101

Participate Sites
1Sites

Terminated1Sites

2019-06-01 - 2021-08-01

Phase III

Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion

  • Condition/Disease

    Spinal Muscular Atrophy Type 1

  • Test Drug

    AVXS-101

Participate Sites
1Sites

Recruiting1Sites

2016-03-11 - 2021-04-19

Phase II/III

A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A

  • Condition/Disease

    Molybdenum Cofactor Deficiency (MoCD) Type A

  • Test Drug

    ALXN1101

Participate Sites
1Sites

Terminated1Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB